Although larger-scale clinical studies need to be performed to use TXNIP as a biomarker in the clinic, TXNIP appears to be a preferred therapeutic target in endothelial and vascular dysfunction to prevent cardiovascular complications associated with age, metabolic disorders, and oxidative stress-related disorders. The gene discussed is TXNIP; the disease is metabolic disease.